Dermatophytic Onychomycosis Therapeutic Drugs Market : North America to Account for Close to 50% Global Market Share
Advancements in medicine, diagnosis of varieties of illnesses, and increasing elder population at an unprecedented rate have resulted in high demand for novel drugs and therapies for dermatophytic onychomycosis treatment. In 2021, the dermatophytic onychomycosis therapeutics market was valued at nearly US$ 5.5 Bn, and is set to experience a 6.5% CAGR over the forecast period (2022-2031).
Request For Free Sample Report of “Dermatophytic Onychomycosis Therapeutic Drugs Market”@ https://www.persistencemarketresearch.com/samples/5840
Presence and availability of a large clinical pipeline with reference to therapeutic approaches based on dermatophytic onychomycosis treatment are set to drive market growth over the coming years. According to the European Commission, more than one fifth, i.e., 20.3% of the population in EU-27 countries was aged 65 and over in 2020. According to WHO, approximately, 80% to 85% of onychomycosis occurs in patients aged above 50 years. High prevalence of age-related disease incidence has led to an increase in the demand for biologics for therapeutic induction for dermatophytic onychomycosis treatment.
Furthermore, social conditions such as poverty, race, and social groups possess an extremely varied rate of occurrence of onychomycosis. These social disparities, together with the presence of a large populace under poverty, is a chief driver of the growth of onychomycosis.
Key Takeaways from Market Study
- By treatment type, drugs are expected to hold 74.8% market value share by the end of 2032, primarily due to rising activities by key players in the drug development biosphere.
- Distal subungual onychomycosis, by indication, is leading with 78.3% market share in 2021, owing to it being a common factor of occurrence associated with age.
- The male segment, by gender, is leading with 61.7% market share in 2021, Males are reported to be more susceptible to onychomycosis with the most probable associated hypothesis being occupational factors as well as lower treatment compliance.
- Age group between 18-39 years is expected to hold more than half of the market value share by the end of 2032.
- Retail sales dominated the end user segments with a share of around 56.2% in 2021.
- By region, North America is the leading region with an expected value share of 48.4% by 2032.
“Rising geriatric population and high prevalence of onychomycosis in the elderly age group are set drive dermatophytic onychomycosis therapeutics,” says an analyst of Persistence Market Research.
Buy Full Report Now and Get Up to 20% Discount @ https://www.persistencemarketresearch.com/checkout/5840
Market Competition
Key market players such as Bausch Health and Dr. Reddy’s Laboratories, amongst others, are involved in research activities in the life sciences sphere. These key players also imbibe the strategy of partnerships and strategic collaborations to expand their geographical product footprint and drive sales is emerging economical territories.
For instance, in December 2021, Bausch Health Ortho Dermatologics the announced JUBLIA® (efinaconazole) Topical Solution, 10%, for onychomycosis treatment, which has received the American Podiatric Medical Association (APMA) seal of approval.
In June 2020, Dr. Reddy’s Laboratories acquired the branded generics business of Wockhardt Limited in Indiam Nepal, Sri Lanka, Bhutan, and the Maldives.
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the dermatophytic onychomycosis therapeutics market in its latest study, presenting historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.
The research study is based on the treatment type (drugs ((oral (Rx and OTC), (topical (Rx and OTC)), Laser (C02 ablative lasers, Nd:YAG lasers and dual-wave length near-infrared lasers)) and photodynamic therapy), indication (distal subungual onychomycosis , white superficial onychomycosis, proximal subungual onychomycosis, candidal onychomycosis and total dystrophic onychomycosis), gender (male and female), age group (0-18 years, 18-39 years, 40-64 years and 65 years and above), and end user (institutional sales (hospitals and dermatology clinics)) and retail sales (retail pharmacies, drug stores and mail order pharmacies & online sales)), across seven key regions of the world.
Request Customization @ https://www.persistencemarketresearch.com/request-customization/5840
Key Questions Answered in This Report.
- What are the Roadblocks for Dermatophytic Onychomycosis Therapeutic Drugs Market Suppliers?
- What are the Key Opportunities for Dermatophytic Onychomycosis Therapeutic Drugs Market Manufacturers?
- How is Focus on Safety Influencing Dermatophytic Onychomycosis Therapeutic Drugs Market Demand?
- What is the Regulatory Impact on Global Sales of Dermatophytic Onychomycosis Therapeutic Drugs Market?
- Which Region Offers the Largest Opportunity for Sales of Dermatophytic Onychomycosis Therapeutic Drugs Market?
- Where Does the U.S. Stand in the Market for Dermatophytic Onychomycosis Therapeutic Drugs Market?
- What Is the Outlook for Dermatophytic Onychomycosis Therapeutic Drugs Market Manufacturers in China?
- Why is Germany a Lucrative Market for Dermatophytic Onychomycosis Therapeutic Drugs Market Manufacturers?
- Why Will Belgium Outpace Other European Markets for Dermatophytic Onychomycosis Therapeutic Drugs Market?
- Why is There High Demand for Tires in Dermatophytic Onychomycosis Therapeutic Drugs Market?
- Why are Sales of Dermatophytic Onychomycosis Therapeutic Drugs Market Surging?
Related Market Reports:
The study also includes statistics as well as facts related to the macroeconomic factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the real-time PCR (qPCR) market..
Sleep Aid Devices Market is anticipated to account for over US$ 29,200 Mn, in terms of value, by 2026 end. The report on the sleep aid devices market further projects significant growth potential with CAGR at 4.9% through 2026..
About Us
Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
Contact Us:
Persistence Market Research
Japan
Persistence Market Research
1-2-1 Kinshi Arca Central Building 14/F Tokyo, 130-0013 Japan
Call 0800-222-1088
United States
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
This Press Release has been written with the intention of providing accurate market information which will enable our readers to make informed strategic investment decisions. If you notice any problem with this content, please feel free to reach us on mediarelations@xherald.com.
